PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration

Tumor Biology

Volumn 35, Issue 9, 2014, Pages 8659-8664

  Che, Huan yong ^a   Guo, Hang yuan ^a   Si, Xu wei ^a   You, Qiao ying ^a   Lou, Wei ying ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Anaplastic thyroid carcinoma; Migration; Phosphoinositide kinase; PP121; Proliferation; Tyrosine

Indexed keywords

ANTINEOPLASTIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PP 121; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; PHOSPHATIDYLINOSITOL KINASE; PP121 COMPOUND; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SIZE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LOADING DRUG DOSE; LOW DRUG DOSE; MOUSE; NONHUMAN; THYROID CARCINOMA; TREATMENT DURATION; TUMOR INVASION; TUMOR XENOGRAFT; WEIGHT REDUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; FLUORESCENCE MICROSCOPY; METABOLISM; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TIME; TUMOR CELL LINE; TUMOR VOLUME;

1-PHOSPHATIDYLINOSITOL 4-KINASE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; IMMUNOHISTOCHEMISTRY; MICE, NUDE; MICROSCOPY, FLUORESCENCE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION; THYROID CARCINOMA, ANAPLASTIC; THYROID NEOPLASMS; TIME FACTORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84919841247     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1007/s13277-014-2118-3     Document Type: Article

References (25)

1. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13(4):453–64.
2. Sun C, Xu X, Wang X, et al. Thymic carcinoma with tumor thrombus protruding into the superior vena cava and the right atrium. Thoracic Cancer. 2013;4(3):333–4.
3. Zhang J, Wang H, Tian W, et al. Brown tumor of the rib as a first presentation of primary hyperparathyroidism: report of three cases and literature review. Thoracic Cancer. 2013;4(4):474–8.
4. Wiseman SM, Masoudi H, Niblock P, et al. Anaplastic thyroid carcinoma: expression profile of targets for therapy offers new insights for disease treatment. Ann Surg Oncol. 2007;14(2):719–29.
5. Bruni P, Boccia A, Baldassarre G, et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1. Oncogene. 2000;19(28):3146–55.
6. Weng LP, Gimm O, Kum JB, et al. Transient ectopic expression of PTEN in thyroid cancer cell lines induces cell cycle arrest and cell type-dependent cell death. Hum Mol Genet. 2001;10(3):251–8.
7. Dahia PL, Marsh DJ, Zheng Z, et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. Cancer Res. 1997;57(21):4710–3.
8. Gimm O, Perren A, Weng LP, et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue and benign and malignant epithelial thyroid tumors. Am J Pathol. 2000;156(5):1693–700.
9. Ringel MD, Hayre N, Saito J, et al. Overexpression and overactivation of Akt in thyroid carcinoma. Cancer Res. 2001;61(16):6105–11.
10. García-Rostán G, Costa AM, Pereira-Castro I, et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res. 2005;65(22):10199–207.
11. Ha HT, Lee JS, Urba S, et al. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid. 2010;20(9):975–80.
12. Zhang J, Wang P, Dykstra M, et al. Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer. J Pathol. 2012;228(2):241–50.
13. Kim MJ, Kim SK, Park HJ, et al. PDGFRA promoter polymorphisms are associated with the risk of papillary thyroid cancer. Mol Med Rep. 2012;5(5):1267–70.
14. Malkomes P, Oppermann E, Bechstein WO, et al. Significantly high expression of platelet-derived growth factor (PDGF) in benign nodules of the thyroid: relevance in the development of goitre recurrence? Langenbecks Arch Surg. 2011;396(8):1165–72.
15. Chen KT, Lin JD, Liou MJ, et al. An aberrant autocrine activation of the platelet-derived growth factor alpha-receptor in follicular and papillary thyroid carcinoma cell lines. Cancer Lett. 2006;231(2):192–205.
16. Apsel B, Blair JA, Gonzalez B, et al. Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008;4(11):691–9.
17. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.
18. Cantley LC. The phosphoinositide 3-kinase pathway. Science (New York, NY). 2002;296(5573):1655–7.
19. Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004;9(6):667–76.
20. Oka N et al. Galectin-3 inhibits tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by activating Akt in human bladder carcinoma cells. Cancer Res. 2005;65(17):7546–53.
21. Moses SA et al. In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT. Cancer Res. 2009;69(12):5073–81.
22. Kundra V, Escobedo JA, Kazlauskas A, et al. Regulation of chemotaxis by the platelet-derived growth factor receptor-beta. Nature. 1994;367(6462):474–6.
23. Hirai H, Sootome H, Nakatsuru Y, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010;9(7):1956–67.
24. Engelman JA et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007;316:1039–43.
25. Sergina NV et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007;445:437–41.